Dextromethorphan/quinidine

Nov 12, 2019

Avanir Pharmaceuticals, Inc. to Continue Clinical Development of Investigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia

Sep 26, 2019

Avanir Pharmaceuticals Announces Resolution of Government Investigation

Mar 25, 2019

Avanir Pharmaceuticals, Inc. Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia

Feb 13, 2019

Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules

Dec 01, 2017

Amarantus Provides Comprehensive Corporate Update

Sep 18, 2017

Urovant Sciences Appoints Keith A. Katkin as Chief Executive Officer

Jun 07, 2017

Avanir Pharmaceuticals Initiates Phase II Study to Evaluate AVP-786 for Treatment of Neurobehavioral Disinhibition Associated with Traumatic Brain Injury